ANZICS CTG Endorsed Study
Hypothermia has been shown to provide a protective effect after renal injury in animal models. However, there has been little clinical investigation of the renal effects of hypothermia. Taking advantage of the opportunity offered by the POLAR multicentre randomised controlled trial of hypothermia in traumatic brain injury (TBI), this substudy will investigate whether in patients with TBI: a) early and sustained hypothermia reduces the severity, incidence and duration of Acute Kidney Injury (AKI); b) the release of biomarkers of kidney injury including NGAL is reduced by cooling compared to maintenance of normothermia; c) the release of biomarkers of kidney injury including NGAL will predict the severity, occurrence and duration of AKI in patients with TBI.
This study provides a unique opportunity to evaluate the benefit of early and sustained hypothermia as a treatment for AKI and may provide insight into the mechanisms of action of hypothermia in AKI. Study of the biomarkers will provide unprecedented insight into their release and performance as markers of AKI and their response to therapy.
Elizabeth Moore (Chair / Project Manager), Michael Bailey, Rinaldo Bellomo, and Alistair Nichol.
ANZIC Research Centre, Monash University
500 patients – POLAR-AKI; 53 patients – POLAR-Biomarkers.
Intensive Care Foundation (joint funding for EPO-TBI and POLAR renal substudies) $13,553.
Project Status as of June 2018
Results are embargoed and the substudy cannot be completed until the POLAR parent study is published.
Elizabeth Moore (email)
ACTRN12609000764235 (POLAR Study)